Main > > >GLIOBLASTOMA. *

---

TREAT.: BevacizuMAb. BioSimilar.
(Recurrent).
USA Launch Date: 2019. 07.18.
(*) Company : Amgen.
TradeMark: MVASI™
UpDate: 2019. 11.12.




TREAT.: BevacizuMAb. BioSimilar.
(Recurrent).
USA Approval Date: 2019. 06.28.
(*) Company : Pfizer.
TradeMark: ZIRABEV
UpDate: 2020. 01.08.




TREAT.L Electric Fields.
(Newly DIAG. & RECURRENT)
CN Approval Date : 2020. 05.13.
JP Approval Date : 2016. 12.19.
USA Approval Date: 2016. 07.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 10.02.




TREAT.: Minimally Invasive Laser Interstitial Thermal Therapy (LITT) Tool>
>Favorable 12-Month Outcomes for
Patients Receiving Minimally Invasive
Laser Ablation for Brain Tumors
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 04.26.




>GLIOBLASTOMA. *'s products
This section has no products